Company intelligence / Profile preview

Isoprene Pharmaceuticals

Baltimore, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Isoprene Pharmaceuticals is conducting advanced preclinical studies developing oral small molecule protein degraders (RAMBAs, MNK1/2 molecular glues) targeting hard-to-treat cancers such as triple negative breast cancer; main candidate VNLG-152 has demonstrated efficacy in preclinical cancer and dermatological models[1][5][6][7].

Therapeutic areas: OncologyDermatologyGastroenterology
Modalities: Small moleculeDegradable molecular glue
Industry: Biotech

Partnerships

Hoth Therapeutics (licensing agreement for VNLG-152 for dermatological diseases)[6]Weill Cornell Medicine (preclinical testing partner)[6]University of Maryland, Baltimore (originator/new venture incubator)[1][6][7]

Beyond the preview

Go deeper on Isoprene Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Isoprene Pharmaceuticals.

Explore the full profile